Assessment of Bone Fragility in Patients with Multiple Myeloma Using QCT-Based Finite Element Modelling. Campbell GM et al. J Bone Miner Res. 2016 Jul 25. doi: 10.1002/jbmr.2924. [Epub ahead of print]. Intracranial Involvement by Plasma Cell Neoplasms. Wilberger AC et al. Am J Clin Pathol. 2016 Jul 24. pii: aqw058. [Epub ahead of print]. Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient…
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print]. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print]. Peripheral blood stem cells collection…
A study published recently in Nature Communications has identified eight new genetic risk loci for myeloma, providing further insights into the genetic and biological basis of its predisposition. The research, performed at The Institute of Cancer Research (ICR) and part funded by Myeloma UK involved a meta-analysis of pooled data from several independent genome-wide association…
Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Muchtar E et al. Hematol Oncol. 2016 Jun 21. doi: 10.1002/hon.2303. [Epub ahead of print]. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. D’Souza A et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14170. [Epub ahead of print].…
The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications. Hemminki K et al. Sci Rep. 2016 Jun 22;6:28500. doi: 10.1038/srep28500. Next generation sequencing identifies a transcriptional profile that segues with genomic alterations in Waldenström macroglobulinemia. Hunter ZR et al. Blood. 2016 Jun 14. pii: blood-2016-03-708263. [Epub ahead of print]. Short- and long-term outcomes…
Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print]. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii:…
HIF-1α and rapamycin act as genosuppressant in multiple myeloma cells upon genotoxic stress. Coudre C et al. Cell Cycle. 2016 Jun 24:0. [Epub ahead of print]. CA-125 secreting IgG kappa Multiple Myeloma (MM). Boota M et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print]. To B(ortezomib) or Not to B: The Stroma’s the Thing. Krem MM et al. J Pathol. 2016 Jun 24.…
Multiple myeloma: practice patterns across Europe. Raab MS et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14193. [Epub ahead of print]. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Prasad V et al. Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028. Pomalidomide in the management of…
Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. Marn Pernat A et al. Ther Apher Dial. 2016 Jun;20(3):251-5. doi: 10.1111/1744-9987.12432. Effective Removal of x03BA;-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings. Jayaballa M et al. Blood Purif. 2016 Jun 8;42(2):158-159. [Epub ahead of print]. Thirteen treatment…
